Insightec has secured coverage for Medicare beneficiaries in all U.S. states for its MR-guided focused ultrasound device, Exablate Neuro.
The device enables treatment of essential tremor and tremor-dominant Parkinson's disease with incisionless surgery. The U.S. Food and Drug Administration (FDA) cleared the device for use in the U.S. in 2016.
Medicare beneficiaries in 38 U.S. states previously had coverage for the treatment. Exablate Neuro is also available as a covered benefit on 22 independent Blue Cross Blue Shield plans, the company said.
